

## Case Study

# Developing a Dataset with Protein Degrading Enzyme-Substrate Relationships

## The Purpose

A mid-size pharma company sought to create a comprehensive list of human enzyme datasets that have protein degrading enzyme - substrate pairs, along-with their associated effects/degradation levels to support their internal research.

## About the Client

**COMPANY**  
Mid-size pharma

**LOCATION**  
Europe

**THERAPEUTIC AREA**  
Protein degradation

## Client Requirement

The client required a comprehensive list of protein degrading enzymes and their specific substrates to support their internal organizational needs. The objective was to utilize Excelra's proprietary text mining pipeline to identify and create this list.


## The Excelra Approach

The objective of the project was to develop a dataset with experimentally proved enzyme -substrate pairs along-with their specific levels of protein degradation. The solution strategy implemented was outlined in 3 different phases.


- 'Phase 1' involved developing a comprehensive list of human protein degrading enzymes.
- 'Phase 2' elaborated on building a literature mining tool to extract relevant articles.
- 'Phase 3' focused on manually curating the relevant articles to develop a dataset and a user interface (UI) to visualize the output data.

## 3 Phased solution strategy


### Phase 1, Preparing the consolidated list of human proteases



### Phase 2, Developing a text mining pipeline and extracting the relevant data








### Phase 3, Manual curation of extracted relevant articles



## Excelra's Contribution

Using our proprietary text mining pipeline, we provided the client with a comprehensive list of relevant enzymes and experimentally approved enzyme-substrate pairs, along-with their associated levels of degradation effects, which helped the client to start a new program at their end.

## Excelra's Service Portfolio

	Insights	Data
 <b>Discovery</b>	<ul style="list-style-type: none"><li>• Data Science Driven Drug Discovery</li><li>• Target Identification</li><li>• Target Dossier Services</li></ul>	<ul style="list-style-type: none"><li>• Chemistry Curation Services</li><li>• GOSTAR Structure Activity Relationship database</li></ul>
 <b>Translational</b>	<ul style="list-style-type: none"><li>• Biomarker Discovery</li><li>• Drug Repositioning</li><li>• Life Cycle Management</li><li>• Systems Biology Informatics</li></ul>	<ul style="list-style-type: none"><li>• Biology Curation Services</li><li>• GOBIOM Biomarker intelligence database</li></ul>
 <b>Clinical</b>	<ul style="list-style-type: none"><li>• Precision Oncology Informatics</li><li>• Clinical Pharmacology</li></ul>	<ul style="list-style-type: none"><li>• Clinical Trial Outcomes Database</li></ul>
 <b>Value Evidence</b>	<ul style="list-style-type: none"><li>• Outcomes Research</li><li>• Epidemiology Modelling</li><li>• Economic Modelling</li><li>• Value Evidence Communication</li></ul>	<ul style="list-style-type: none"><li>• RWE &amp; Big Data Realization</li><li>• SLR &amp; Meta-analysis</li></ul>
 <b>Technology Solutions</b>	<ul style="list-style-type: none"><li>• Enterprise Data Strategy</li><li>• Enterprise Cloud Ops</li><li>• Enterprise Digital Transformation</li></ul>	

For more information, visit [https://www.excelra.com/translational/#biology\\_curation](https://www.excelra.com/translational/#biology_curation)



### About Excelra

Excelra's data and analytics solutions empower innovation in life sciences across the value chain from discovery to market. The Excelra Edge comes from a seamless amalgamation of proprietary curated data assets, deep domain expertise and data science. The company's multifaceted teams harmonize and analyse large volumes of disparate unstructured data using cutting-edge technologies. We galvanize data-driven decisions to unlock operational efficiencies to accelerate drug discovery and development. Over the past 18 years, Excelra has been the preferred data and analytics partner to over 90 global clients, including 15 of the top 20 large Pharma.